Scholarlink

Purpose <p>To investigate the long-term risk factors for post-operative vitreous hemorrhage (VH) within 24 months following vitrectomy for proliferative diabetic retinopathy (PDR), evaluate the protective efficacy of preoperative anti-VEGF therapy, and quantify the associated secondary surgical burden.</p> Methods <p>This retrospective cohort study included 735 eyes from 735 PDR patients. A 24-month survival analysis was employed to categorize patients into VH (<i>n</i> = 179) and non-VH (<i>n</i> = 556) groups. Independent predictors were identified using univariate and multivariate Cox proportional hazards models. A sensitivity analysis was performed on a “pure hemorrhage model” (<i>n</i> = 676) by excluding eyes with post-operative tractional retinal detachment (TRD) to isolate the direct vascular-stabilizing effect of anti-VEGF.</p> Results <p>The overall cumulative incidence of post-operative VH was 18.4% at 12 months and 25.7% at 24 months. Multivariate Cox analysis revealed that preoperative anti-VEGF injection emerged as the strongest protective factor, associated with a 63% reduction in VH hazard (HR 0.37; 95% CI, 0.27–0.51; <i>P</i> &lt; 0.001). This protective effect remained robust in the sensitivity analysis (HR 0.32; <i>P</i> &lt; 0.001), which is consistent with a potential vascular-stabilizing effect independent of anatomical success. Independent risk factors included severe fibrovascular traction (HR 1.93; <i>P</i> = 0.003), younger age, higher HbA1c, and elevated serum creatinine (all <i>P</i> &lt; 0.05). Patients in the VH group had significantly poorer final visual outcomes (1.33 ± 0.75 vs. 0.92 ± 0.60 LogMAR; <i>P</i> &lt; 0.001) and a markedly higher reoperation rate (31.3% vs. 7.2%). Notably, hemorrhage-related indications accounted for 58.4% of the total secondary surgical workload.</p> Conclusion <p>Post-operative VH is a dominant driver of long-term visual impairment and secondary surgical burden in PDR. Preoperative anti-VEGF supports the hypothesis that preoperative anti-VEGF may contribute to sustained microvascular stabilization. Vitreous hemorrhage-related indications accounted for 58.4% of secondary surgical interventions, suggesting that clinical strategies aimed at reducing recurrent VH could meaningfully decrease the overall reoperation burden in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preoperative anti-VEGF and the cumulative risk of post-operative vitreous hemorrhage in PDR: a 2-year survival analysis and evaluation of surgical burden

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Yuxian Lin,
  • Ruibin Wu,
  • Gengjia Li

摘要

Purpose

To investigate the long-term risk factors for post-operative vitreous hemorrhage (VH) within 24 months following vitrectomy for proliferative diabetic retinopathy (PDR), evaluate the protective efficacy of preoperative anti-VEGF therapy, and quantify the associated secondary surgical burden.

Methods

This retrospective cohort study included 735 eyes from 735 PDR patients. A 24-month survival analysis was employed to categorize patients into VH (n = 179) and non-VH (n = 556) groups. Independent predictors were identified using univariate and multivariate Cox proportional hazards models. A sensitivity analysis was performed on a “pure hemorrhage model” (n = 676) by excluding eyes with post-operative tractional retinal detachment (TRD) to isolate the direct vascular-stabilizing effect of anti-VEGF.

Results

The overall cumulative incidence of post-operative VH was 18.4% at 12 months and 25.7% at 24 months. Multivariate Cox analysis revealed that preoperative anti-VEGF injection emerged as the strongest protective factor, associated with a 63% reduction in VH hazard (HR 0.37; 95% CI, 0.27–0.51; P < 0.001). This protective effect remained robust in the sensitivity analysis (HR 0.32; P < 0.001), which is consistent with a potential vascular-stabilizing effect independent of anatomical success. Independent risk factors included severe fibrovascular traction (HR 1.93; P = 0.003), younger age, higher HbA1c, and elevated serum creatinine (all P < 0.05). Patients in the VH group had significantly poorer final visual outcomes (1.33 ± 0.75 vs. 0.92 ± 0.60 LogMAR; P < 0.001) and a markedly higher reoperation rate (31.3% vs. 7.2%). Notably, hemorrhage-related indications accounted for 58.4% of the total secondary surgical workload.

Conclusion

Post-operative VH is a dominant driver of long-term visual impairment and secondary surgical burden in PDR. Preoperative anti-VEGF supports the hypothesis that preoperative anti-VEGF may contribute to sustained microvascular stabilization. Vitreous hemorrhage-related indications accounted for 58.4% of secondary surgical interventions, suggesting that clinical strategies aimed at reducing recurrent VH could meaningfully decrease the overall reoperation burden in this population.